CDIONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as CDIOW
Cardio Diagnostics Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.64−0.05 (-2.96%)
Close on Oct 19, 2026
- Market cap
- $4.85M
- P/E (TTM)
- –
- Dividend yield
- –
Cardio Diagnostics Holdings, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -43737.5%
- Net margin
- -43832.5%
- Return on equity, FY2025
- -78.6%
Financial strength
- Current ratio
- 17.15
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 0.0%
Valuation
- P/E ratio
- –
- Price to sales
- 327.39
- Price to book
- 0.65
- Dividend yield
- –